The trial achieved its primary endpoint, showing a statistically significant reduction in Valsalva LVOT gradient at week 28.

Bristol Myers Squibb today announced positive topline results from SCOUT-HCM, a Phase 3 trial evaluating Camzyos (mavacamten) ...

The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic ...

MYQORZO is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. MYQORZO is contraindicated with ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Background: Hypertrophic obstructive cardiomyopathy (HOCM) is an autosomal dominant genetic disorder. Invasive treatment for intraventricular gradient reduction is indicated in patients (p) who are ...

Hypertrophic cardiomyopathy (HCM) is a genetic condition in which the heart muscle thickens abnormally, increasing ones risk of several serious heart complications. The muscle thickening disrupts ...

Arrhythmias, or irregular heart rhythms, are common complications of HCM. The thickened heart muscle disrupts the electrical pathways that coordinate heartbeat, leading to arrhythmias. Atrial ...

1. Erasmus MC Center of Expertise for Inherited Cardiovascular Diseases, Rotterdam, the Netherlands 2. Centre for Heart Muscle Disease, University College London (UCL), UK 3. Inherited Cardiovascular ...